Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Tebentafusp in Uveal Melanoma: NCT07276386 Clinical Landscape Report 2026
28 September 2026
NCT07276386 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Toripalimab in Muscle Invasive Bladder Urothelial Carcinoma: NCT07279597 Clinical Landscape Report 2026
28 September 2026
NCT07279597 clinical landscape for Muscle Invasive Bladder Urothelial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
Pafolacianine in Endometrial Carcinoma: NCT07278986 Clinical Landscape Report 2026
28 September 2026
NCT07278986 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti-CD19/BCMA CAR-NK Cells(The Children's Hospital of Zhejiang University School of Medicine) in Scleroderma: NCT07283315 Clinical Landscape Report 2026
28 September 2026
NCT07283315 clinical landscape for Scleroderma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Toripalimab in Non-Muscle Invasive Bladder Neoplasms: NCT07307456 Clinical Landscape Report 2026
28 September 2026
NCT07307456 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Cretostimogene Grenadenorepvec in Non-Muscle Invasive Bladder Neoplasms: NCT07283835 Clinical Landscape Report 2026
28 September 2026
NCT07283835 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Tislelizumab in HER2 Positive Muscle Invasive Bladder Carcinoma: NCT07296705 Clinical Landscape Report 2026
28 September 2026
NCT07296705 clinical landscape for HER2 Positive Muscle Invasive Bladder Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develop…
9 min read
BCT301 Cell(Peking University Third Hospital) in Idiopathic Inflammatory Myopathies: NCT07301164 Clinical Landscape Report 2026
28 September 2026
NCT07301164 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
SHR-2173 in Systemic Lupus Erythematosus: NCT07299422 Clinical Landscape Report 2026
28 September 2026
NCT07299422 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Universal allogeneic anti-CD19/BCMA CAR T-cells(The Children's Hospital of Zhejiang University School of Medicine) in Granulomatosis With Polyangiitis: NCT07305116 Clinical Landscape Report 2026
28 September 2026
NCT07305116 clinical landscape for Granulomatosis With Polyangiitis: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
HC022 in Lupus Erythematosus, Cutaneous: NCT07306585 Clinical Landscape Report 2026
28 September 2026
NCT07306585 clinical landscape for Lupus Erythematosus, Cutaneous: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nomelcitinib in Systemic Lupus Erythematosus: NCT07311200 Clinical Landscape Report 2026
28 September 2026
NCT07311200 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.